PGO0 Stock Chart & Stats
€0.05
-€0.02(-2.92%)
At close: 4:00 PM EST
€0.05
-€0.02(-2.92%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€7.58M
Enterprise Value€6.47
Total Cash (Recent Filing)€9.07M
Total Debt (Recent Filing)€5.30M
Price to Earnings (P/E)―
Beta-2.29
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding532,703,900
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.38
Price to Sales (P/S)17.06
P/FCF Ratio-0.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€111.75K
Bulls Say, Bears Say
Bulls Say
Positive Equity Cushion And Moderate LeveragePositive equity and moderate leverage provide a financial cushion relative to the company’s losses. This may preserve some flexibility to fund commercialization and operations, although continued losses could reduce that cushion over time.
Operating Cash Burn Improved Year Over YearThe improvement in operating cash flow indicates some progress in controlling cash consumption. If sustained alongside stronger test adoption, it could extend funding capacity and reduce the pace at which external capital is required.
Losses Have Not Meaningfully WidenedRelative stability in losses suggests the company has not experienced a clear acceleration in operating deterioration despite its development-stage profile. This provides a base for improvement if revenue scales and the cost structure becomes more efficient.
Bears Say
Recent Revenue DeclineRecent revenue contraction indicates that commercial adoption of the prostate cancer testing offering remains insufficient or inconsistent. Sustained growth is needed to support operating leverage, validate market demand, and reduce dependence on external funding.
Deep Losses And Negative Gross MarginNegative gross profit means current sales do not cover direct costs, while operating losses show that fixed expenses remain unsupported. Without material improvement in pricing, test volumes, or laboratory efficiency, profitability remains structurally distant.
Persistent Cash Burn And Declining EquityPersistent cash consumption and a declining equity base increase the risk of future financing needs and potential dilution. The company remains dependent on revenue scaling or cost reductions to become financially self-sustaining.
PGO0 FAQ
What was Prostatype Genomics AB’s price range in the past 12 months?
Prostatype Genomics AB lowest stock price was <€0.01 and its highest was €0.05 in the past 12 months.
What is Prostatype Genomics AB’s market cap?
Prostatype Genomics AB’s market cap is €7.58M.
When is Prostatype Genomics AB’s upcoming earnings report date?
Prostatype Genomics AB’s upcoming earnings report date is Aug 31, 2026 which is in 2 days.
How were Prostatype Genomics AB’s earnings last quarter?
Prostatype Genomics AB released its earnings results on Feb 26, 2026. The company reported -€0.014 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Prostatype Genomics AB overvalued?
According to Wall Street analysts Prostatype Genomics AB’s price is currently Overvalued.
Does Prostatype Genomics AB pay dividends?
Prostatype Genomics AB does not currently pay dividends.
What is Prostatype Genomics AB’s EPS estimate?
Prostatype Genomics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prostatype Genomics AB have?
Prostatype Genomics AB has 532,703,900 shares outstanding.
What happened to Prostatype Genomics AB’s price movement after its last earnings report?
Prostatype Genomics AB reported an EPS of -€0.014 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.846%.
Which hedge fund is a major shareholder of Prostatype Genomics AB?
Currently, no hedge funds are holding shares in DE:PGO0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prostatype Genomics AB
Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason Score, and Tumor Stage to determine a specific P-score. This advanced diagnostic tool is built upon a vast database of prostate cancer patients, providing crucial support for patients and medical practitioners when deciding on treatment strategies. Founded in 2007, the company is headquartered in Solna, Sweden.
Technical Analysis
Immunovia AB
―
Q-linea AB
―
Acarix AB
―
Biovica International AB Class B
―
Devyser Diagnostics AB
―